POS0714 TREAT-TO-TARGET RECOMMENDATIONS IN GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA

Background The treat-to-target (T2T) concept is not yet a recognized treatment approach in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). Developing such recommendations an unmet medical need. Objectives To determine therapeutic targets develop GCA PMR. Methods We conducted systematic literature review to retrieve data on outcomes GCA/PMR as well identify the evidence for effectiveness of T2T-based management approaches these diseases. Based expert opinion, task force [29 participants from 10 countries (physicians, healthcare professional patient)] developed recommendations, with consensus obtained through voting. final level agreement was provided anonymously. Results Five overarching principles six specific were formulated (Table 1). Key messages are that PMR should be based shared decisions between patient physician, underpinning need urgent avoid ischemic complications, it aim at maximizing health-related quality life both achievement maintenance remission (still ultimate validation), prevention tissue ischemia vascular damage. Comorbidities considered when assessing disease activity selecting treatment. Conclusion These first T2T Treatment strategies assess, achieve maintain have been defined. research agenda highlights evidence-gaps needs future research. Table 1. Treat-to-Target Overarching LoE LoA A. Clinical driven by awareness they closely interrelated conditions common spectrum inflammatory can occur separately, simultaneously or temporal sequence each other. n.a. 9.8 96.3% > 8 B. emergency because imminent risk sight loss other events therefore requires immediate treatment; usually multidisciplinary collaboration. 9.9 100% C. Patients offered access information about PMR, including clinical features, reported outcomes, potential related benefits risks, relevant comorbidities. 9.7 D. Management decision making informed physician. E. control symptoms, preventing disease-related damage minimizing treatment-related adverse consequences, taking comorbidities into account. Recommendations target remission; absence symptoms systemic inflammation. 5 9.6 2. also prevent 3. selection severity activity, presence predictors outcome; modified needed during follow-up. 4. may influence assessment before modifying 5. Once reached, maintained minimal effective dose medication # ; drug-free achieved proportion patients ## . - 2 6. Disease monitored regularly, frequently every 1-4 weeks until has achieved, longer monitoring intervals (for example 3 6 months) stable therapy; off therapy discussed individual basis. LoE: Level Evidence; LoA: Agreement Acknowledgements Funding conduct this project AbbVie. authors would like thank Louise Falzon her work development search strategy. Disclosure Interests Christian Dejaco Speakers bureau: Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos Sanofi, Consultant of: Galapagos, Sparrow Grant/research support from: AbbVie, Andreas Kerschbaumer Amgen, Bristol-Myers Squibb, Gilead, Merck Sharp Dohme, UCB Daniel Aletaha Merck, Sandoz, Milena Bond: None declared, Elvis Hysa: Dario Camellino Abiogen, BMS GSK, Lisa Ehlers: Andy Abril: Simone Appenzeller: Maria Cid GSK SCL-Vifor, Vifor, Kiniksa Pharmaceuticals, Bhaskar Dasgupta Chugai, Christina Duftner AOP Orphan, Astra-Zeneca, Bristol-Myers-Squibb, Eli-Lilly, Merck-Sharp-Dohme, UCB, Peter Grayson: Bernhard Hellmich BMS, Boehringer, InflaRx, MSD, Phadia, Roche ALOJZIJA HOCEVAR: Tanaz Kermani: Eric Matteson Boehringer-Ingelheim, Horizon Therapeutics, Alvotech Inc, Susan Mollan Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Teva UK; Chiesi; Santhera, Invex Gensight, Lorna Neill: Cristina Ponte AstraZeneca, GlaxoSmithKline, Sanofi Carlo Salvarani Pfizer Sebastian Sattui Rheumatology Research Foundation RISE pilot award Bristol Myers Squibb Robert Winn Diversity Trials Career Development Award, Wolfgang Schmidt Johnson & Johnson, Medac, Philip Seo Amgen Josef Smolen Astro, Celltrion, Novartis-Sandoz, R-Pharm, Samsung, Novartis Jens Thiel Glaxo-Smith-Kline, CARLOS TORO GUTIÉRREZ Boehringer Ingelheim, Biopas, Pharmalab, Madeline Whitlock Frank Buttgereit Sanofi.